Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 12/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18591124 | 0.89 | FKBP1A (0.45) | KLK7FKBP1ACTSLPDK1PDK2 | |
| SCHEMBL6788747 | 0.89 | FKBP1A (0.45) | KLK7FKBP1ACTSLPDK1PDK2 | |
| SCHEMBL934333 | 0.88 | KLK7 (0.47) | KLK7FKBP1ACTSLMEN1KMT2A | |
| SCHEMBL18084468 | 0.88 | KLK7 (0.47) | KLK7FKBP1ACTSLMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL26098363 | 0.87 | KLK7 (0.46) | KLK7FKBP1ACTSLMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL26098360 | 0.87 | KLK7 (0.46) | KLK7FKBP1ACTSLMEN1KMT2A | |
| SCHEMBL18018255 | 0.84 | FKBP1A (0.44) | KLK7FKBP1ACTSLMEN1KMT2A | |
| SCHEMBL12480502 | 0.84 | FKBP1A (0.44) | KLK7FKBP1ACTSLMEN1KMT2A | |
| SCHEMBL18578105 | 0.84 | FKBP1A (0.44) | KLK7FKBP1ACTSLMEN1KMT2A | |
| SCHEMBL2124213 | 0.84 | NPSR1 (0.48) | FKBP1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111032651-A | Heterocyclic compounds | 武田药品工业株式会社 | 2020-04-17 | — | — | CN | disclosed |
| US-10435399-B2 | HDAC6 inhibitory heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-08 | — | — | US | disclosed |
| US-20190135799-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435399-B2 | HDAC6 inhibitory heterocyclic compound | HDAC6, HDAC1, HDAC5 | KLK7 4645/4885FKBP1A 931/4885CTSL 4422/4885 |
| US-20190135799-A1 | HETEROCYCLIC COMPOUND | HDAC1, HDAC5, HDAC6 | KLK7 4809/4885FKBP1A 685/4885CTSL 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.